Galmed Pharmaceuticals Secures $10M Equity Agreement

Galmed Pharmaceuticals (GLMD) has released an update.

Galmed Pharmaceuticals Ltd., an Israeli company, has entered into a Standby Equity Purchase Agreement with YA II PN, LTD., allowing Galmed to issue and sell up to $10 million of its ordinary shares to the investor. These shares are traded on the Nasdaq Capital Market under the symbol ‘GLMD’ and will be sold pursuant to exemption rules of the Securities Act of 1933. This strategic financial move aims to enhance Galmed’s capital position, providing a flexible way to access funds.

For further insights into GLMD stock, check out TipRanks’ Stock Analysis page.